273 related articles for article (PubMed ID: 31399962)
21. Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease.
Li LX; Fan LX; Zhou JX; Grantham JJ; Calvet JP; Sage J; Li X
J Clin Invest; 2017 Jun; 127(7):2751-2764. PubMed ID: 28604386
[TBL] [Abstract][Full Text] [Related]
22. The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis.
Buchholz B; Klanke B; Schley G; Bollag G; Tsai J; Kroening S; Yoshihara D; Wallace DP; Kraenzlin B; Gretz N; Hirth P; Eckardt KU; Bernhardt WM
Nephrol Dial Transplant; 2011 Nov; 26(11):3458-65. PubMed ID: 21804086
[TBL] [Abstract][Full Text] [Related]
23. The master regulators Myc and p53 cellular signaling and functions in polycystic kidney disease.
Kurbegovic A; Trudel M
Cell Signal; 2020 Jul; 71():109594. PubMed ID: 32145315
[TBL] [Abstract][Full Text] [Related]
24. Coexpression of extracellular matrix glycoproteins undulin and tenascin in human autosomal dominant polycystic kidney disease.
Klingel R; Ramadori G; Schuppan D; Knittel T; Meyer zum Büschenfelde KH; Köhler H
Nephron; 1993; 65(1):111-8. PubMed ID: 7692313
[TBL] [Abstract][Full Text] [Related]
25. Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease.
Chen L; Zhou X; Fan LX; Yao Y; Swenson-Fields KI; Gadjeva M; Wallace DP; Peters DJ; Yu A; Grantham JJ; Li X
J Clin Invest; 2015 Jun; 125(6):2399-412. PubMed ID: 25961459
[TBL] [Abstract][Full Text] [Related]
26. Inactivation of integrin-β1 prevents the development of polycystic kidney disease after the loss of polycystin-1.
Lee K; Boctor S; Barisoni LM; Gusella GL
J Am Soc Nephrol; 2015 Apr; 26(4):888-95. PubMed ID: 25145933
[TBL] [Abstract][Full Text] [Related]
27. STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease.
Fragiadaki M; Lannoy M; Themanns M; Maurer B; Leonhard WN; Peters DJ; Moriggl R; Ong AC
Kidney Int; 2017 Mar; 91(3):575-586. PubMed ID: 28104302
[TBL] [Abstract][Full Text] [Related]
28. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells.
Belibi FA; Reif G; Wallace DP; Yamaguchi T; Olsen L; Li H; Helmkamp GM; Grantham JJ
Kidney Int; 2004 Sep; 66(3):964-73. PubMed ID: 15327388
[TBL] [Abstract][Full Text] [Related]
29. Periostin induces proliferation of human autosomal dominant polycystic kidney cells through alphaV-integrin receptor.
Wallace DP; Quante MT; Reif GA; Nivens E; Ahmed F; Hempson SJ; Blanco G; Yamaguchi T
Am J Physiol Renal Physiol; 2008 Nov; 295(5):F1463-71. PubMed ID: 18753297
[TBL] [Abstract][Full Text] [Related]
30. Kidney: polycystic kidney disease.
Paul BM; Vanden Heuvel GB
Wiley Interdiscip Rev Dev Biol; 2014; 3(6):465-87. PubMed ID: 25186187
[TBL] [Abstract][Full Text] [Related]
31. Cyst expansion and regression in a mouse model of polycystic kidney disease.
Happé H; van der Wal AM; Salvatori DC; Leonhard WN; Breuning MH; de Heer E; Peters DJ
Kidney Int; 2013 Jun; 83(6):1099-108. PubMed ID: 23466997
[TBL] [Abstract][Full Text] [Related]
32. Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells.
Yamaguchi T; Hempson SJ; Reif GA; Hedge AM; Wallace DP
J Am Soc Nephrol; 2006 Jan; 17(1):178-87. PubMed ID: 16319189
[TBL] [Abstract][Full Text] [Related]
33. Interactions between Macrophages and Cyst-Lining Epithelial Cells Promote Kidney Cyst Growth in
Yang Y; Chen M; Zhou J; Lv J; Song S; Fu L; Chen J; Yang M; Mei C
J Am Soc Nephrol; 2018 Sep; 29(9):2310-2325. PubMed ID: 30042193
[TBL] [Abstract][Full Text] [Related]
34. Animal models for human polycystic kidney disease.
Nagao S; Kugita M; Yoshihara D; Yamaguchi T
Exp Anim; 2012; 61(5):477-88. PubMed ID: 23095811
[TBL] [Abstract][Full Text] [Related]
35. Molecular and cellular pathogenesis of autosomal dominant polycystic kidney disease.
Bastos AP; Onuchic LF
Braz J Med Biol Res; 2011 Jul; 44(7):606-17. PubMed ID: 21625823
[TBL] [Abstract][Full Text] [Related]
36. Proliferative signaling by ERBB proteins and RAF/MEK/ERK effectors in polycystic kidney disease.
Parker MI; Nikonova AS; Sun D; Golemis EA
Cell Signal; 2020 Mar; 67():109497. PubMed ID: 31830556
[TBL] [Abstract][Full Text] [Related]
37. Multidrug therapy for polycystic kidney disease: a review and perspective.
Aguiari G; Catizone L; Del Senno L
Am J Nephrol; 2013; 37(2):175-82. PubMed ID: 23428809
[TBL] [Abstract][Full Text] [Related]
38. Renal plasticity revealed through reversal of polycystic kidney disease in mice.
Dong K; Zhang C; Tian X; Coman D; Hyder F; Ma M; Somlo S
Nat Genet; 2021 Dec; 53(12):1649-1663. PubMed ID: 34635846
[TBL] [Abstract][Full Text] [Related]
39. Distribution of alpha-integrin subunits in fetal polycystic kidney diseases.
Daïkha-Dahmane F; Narcy F; Dommergues M; Lacoste M; Beziau A; Gubler MC
Pediatr Nephrol; 1997 Jun; 11(3):267-73. PubMed ID: 9203171
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
